Characterization of woodchuck apolipoprotein A-I: A new tool for drug delivery and identification of altered isoforms in the woodchuck chronic hepatitis model

Journal of Medical Virology

Volumn 83, Issue 7, 2011, Pages 1221-1229

  Fioravanti, Jessica ^a   Gomar, Celia ^a   Medina Echeverz, José ^a   Otano, Itziar ^a   Benito, Alberto ^b   Prieto, Jesús ^a,b   González Aseguinolaza, Gloria ^a   Berraondo, Pedro ^a,b  

^a UNIVERSITY OF NAVARRA   (Spain)

^b UNIVERSITY CLINIC OF NAVARRA   (Spain)

Author keywords

Hepatitis B virus; High density lipoprotein; Scavenger receptor class B type 1

Indexed keywords

APOLIPOPROTEIN A1; HIGH DENSITY LIPOPROTEIN; ISOPROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL CULTURE; CARCINOMA CELL; CHRONIC HEPATITIS; CONTROLLED STUDY; DENSITY GRADIENT CENTRIFUGATION; DRUG DELIVERY SYSTEM; DRUG TARGETING; ISOELECTRIC FOCUSING; MOLECULAR CLONING; NONHUMAN; NUCLEOTIDE SEQUENCE; OPEN READING FRAME; PHYLOGENY; PROTEIN ANALYSIS; WOODCHUCK;

ANIMALS; APOLIPOPROTEIN A-I; BASE SEQUENCE; CARBOCYANINES; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CLONING, MOLECULAR; DISEASE MODELS, ANIMAL; DRUG DELIVERY SYSTEMS; FLOW CYTOMETRY; HEPATITIS B VIRUS, WOODCHUCK; HEPATITIS B, CHRONIC; HUMANS; LIVER; LIVER NEOPLASMS; MARMOTA; MICE; MOLECULAR SEQUENCE DATA; MOLECULAR TARGETED THERAPY; PROTEIN ISOFORMS; TRANSFECTION; VIRUS REPLICATION;

ANIMALIA; HEPATITIS B VIRUS; MARMOTA MONAX; MUS; WOODCHUCK HEPATITIS VIRUS;

EID: 79955910642     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.22104     Document Type: Article

References (51)

1. Balazs Z, Panzenboeck U, Hammer A, Sovic A, Quehenberger O, Malle E, Sattler W. 2004. Uptake and transport of high-density lipoprotein (HDL) and HDL-associated alpha-tocopherol by an in vitro blood-brain barrier model. J Neurochem 89: 939-950.
2. Barth H, Schnober EK, Neumann-Haefelin C, Thumann C, Zeisel MB, Diepolder HM, Hu Z, Liang TJ, Blum HE, Thimme R, Lambotin M, Baumert TF. 2008. Scavenger receptor class B is required for hepatitis C virus uptake and cross-presentation by human dendritic cells. J Virol 82: 3466-3479.
3. Bojanovski D, Gregg RE, Ghiselli G, Schaefer EJ, Light JA, Brewer HB, Jr. 1985. Human apolipoprotein A-I isoprotein metabolism: proapoA-I conversion to mature apoA-I. J Lipid Res 26: 185-193.
4. Brinton EA, Eisenberg S, Breslow JL. 1990. A low-fat diet decreases high density lipoprotein (HDL) cholesterol levels by decreasing HDL apolipoprotein transport rates. J Clin Invest 85: 144-151.
5. Brinton EA, Eisenberg S, Breslow JL. 1991. Increased apo A-I and apo A-II fractional catabolic rate in patients with low high density lipoprotein-cholesterol levels with or without hypertriglyceridemia. J Clin Invest 87: 536-544.
6. Brinton EA, Eisenberg S, Breslow JL. 1994. Human HDL cholesterol levels are determined by apoA-I fractional catabolic rate, which correlates inversely with estimates of HDL particle size. Effects of gender, hepatic and lipoprotein lipases, triglyceride and insulin levels, and body fat distribution. Arterioscler Thromb 14: 707-720.
7. Cao WM, Murao K, Imachi H, Yu X, Abe H, Yamauchi A, Niimi M, Miyauchi A, Wong NC, Ishida T. 2004. A mutant high-density lipoprotein receptor inhibits proliferation of human breast cancer cells. Cancer Res 64: 1515-1521.
8. Connelly MA, Williams DL. 2004. Scavenger receptor BI: A scavenger receptor with a mission to transport high density lipoprotein lipids. Curr Opin Lipidol 15: 287-295.
9. Counsell RE, Pohland RC. 1982. Lipoproteins as potential site-specific delivery systems for diagnostic and therapeutic agents. J Med Chem 25: 1115-1120.
10. Edelstein C, Gordon JI, Toscas K, Sims HF, Strauss AW, Scanu AM. 1983. In vitro conversion of proapoprotein A-I to apoprotein A-I. Partial characterization of an extracellular enzyme activity. J Biol Chem 258: 11430-11433.
11. Feng M, Cai Q, Huang H, Zhou P. 2008a. Liver targeting and anti-HBV activity of reconstituted HDL-acyclovir palmitate complex. Eur J Pharm Biopharm 68: 688-693.
12. Feng M, Cai Q, Shi X, Huang H, Zhou P, Guo X. 2008b. Recombinant high-density lipoprotein complex as a targeting system of nosiheptide to liver cells. J Drug Target 16: 502-508.
13. Fernandez-Irigoyen J, Santamaria E, Sesma L, Munoz J, Riezu JI, Caballeria J, Lu SC, Prieto J, Mato JM, Avila MA, Corrales FJ. 2005. Oxidation of specific methionine and tryptophan residues of apolipoprotein A-I in hepatocarcinogenesis. Proteomics 5: 4964-4972.
14. Fidge NH. 1999. High density lipoprotein receptors, binding proteins, and ligands. J Lipid Res 40: 187-201.
15. Geiss HC, Ritter MM, Richter WO, Schwandt P, Zachoval R. 1996. Low lipoprotein levels during acute viral hepatitis. Hepatology 24: 1334-1337.
16. Gylling H, Vega GL, Grundy SM. 1992. Physiologic mechanisms for reduced apolipoprotein A-I concentrations associated with low levels of high density lipoprotein cholesterol in patients with normal plasma lipids. J Lipid Res 33: 1527-1539.
17. Hamidi M, Foroozesh M, Zarrin A. 2006. Lipoproteins: From physiological roles to drug delivery potentials. Crit Rev Ther Drug Carrier Syst 23: 497-523.
18. He QY, Lau GK, Zhou Y, Yuen ST, Lin MC, Kung HF, Chiu JF. 2003. Serum biomarkers of hepatitis B virus infected liver inflammation: A proteomic study. Proteomics 3: 666-674.
19. Hovorka R, Nanjee MN, Cooke CJ, Miller IP, Olszewski WL, Miller NE. 2006. Mass kinetics of apolipoprotein A-I in interstitial fluid after administration of intravenous apolipoprotein A-I/lecithin discs in humans. J Lipid Res 47: 975-981.
20. Husemann J, Loike JD, Kodama T, Silverstein SC. 2001. Scavenger receptor class B type I (SR-BI) mediates adhesion of neonatal murine microglia to fibrillar beta-amyloid. J Neuroimmunol 114: 142-150.
21. Kim KD, Lim HY, Lee HG, Yoon DY, Choe YK, Choi I, Paik SG, Kim YS, Yang Y, Lim JS. 2005. Apolipoprotein A-I induces IL-10 and PGE2 production in human monocytes and inhibits dendritic cell differentiation and maturation. Biochem Biophys Res Commun 338: 1126-1136.
22. Kim SI, Shin D, Choi TH, Lee JC, Cheon GJ, Kim KY, Park M, Kim M. 2007. Systemic and specific delivery of small interfering RNAs to the liver mediated by apolipoprotein A-I. Mol Ther 15: 1145-1152.
23. Krieger M. 2001. Scavenger receptor class B type I is a multiligand HDL receptor that influences diverse physiologic systems. J Clin Invest 108: 793-797.
24. Lacko AG, Nair M, Paranjape S, Johnso S, McConathy WJ. 2002. High density lipoprotein complexes as delivery vehicles for anticancer drugs. Anticancer Res 22: 2045-2049.
25. Lacko AG, Nair M, Paranjape S, Mooberry L, McConathy WJ. 2006. Trojan horse meets magic bullet to spawn a novel, highly effective drug delivery model. Chemotherapy 52: 171-173.
26. Lisi D, Kondili LA, Ramieri MT, Giuseppetti R, Bruni R, Della Rocca C, De Santis A, Rapicetta M. 2003. Ultrasonography in the study of hepatocellular carcinoma in woodchucks chronically infected with WHV. Lab Anim 37: 233-240.
27. Lou B, Liao XL, Wu MP, Cheng PF, Yin CY, Fei Z. 2005. High-density lipoprotein as a potential carrier for delivery of a lipophilic antitumoral drug into hepatoma cells. World J Gastroenterol 11: 954-959.
28. Magill P, Rao SN, Miller NE, Nicoll A, Brunzell J, St Hilaire J, Lewis B. 1982. Relationships between the metabolism of high-density and very-low-density lipoproteins in man: Studies of apolipoprotein kinetics and adipose tissue lipoprotein lipase activity. Eur J Clin Invest 12: 113-120.
29. McConathy WJ, Nair MP, Paranjape S, Mooberry L, Lacko AG. 2008. Evaluation of synthetic/reconstituted high-density lipoproteins as delivery vehicles for paclitaxel. Anticancer Drugs 19: 183-188.
30. Nanjee MN, Crouse JR, King JM, Hovorka R, Rees SE, Carson ER, Morgenthaler JJ, Lerch P, Miller NE. 1996. Effects of intravenous infusion of lipid-free apo A-I in humans. Arterioscler Thromb Vasc Biol 16: 1203-1214.
31. Nayak SS, Ramani A, Kamath SS, Kundaje GN, Aroor AR. 1988. Serum apoproteins A and B and the lecithin: cholesterol acyl transferase activities in liver cirrhosis and hepatic coma patients. Biochem Med Metab Biol 40: 299-304.
32. Neary RH, Gowland E. 1987. Stability of free apolipoprotein A-1 concentration in serum, and its measurement in normal and hyperlipidemic subjects. Clin Chem 33: 1163-1169.
33. Reboul E, Klein A, Bietrix F, Gleize B, Malezet-Desmoulins C, Schneider M, Margotat A, Lagrost L, Collet X, Borel P. 2006. Scavenger receptor class B type I (SR-BI) is involved in vitamin E transport across the enterocyte. J Biol Chem 281: 4739-4745.
34. Rodriguez-Sureda V, Julve J, Llobera M, Peinado-Onsurbe J. 2002. Ultracentrifugation micromethod for preparation of small experimental animal lipoproteins. Anal Biochem 303: 73-77.
35. Roggendorf M, Tolle TK. 1995. The woodchuck: An animal model for hepatitis B virus infection in man. Intervirology 38: 100-112.
36. Saku K, Liu R, Ohkubo K, Bai H, Hirata K, Yamamoto K, Morimoto Y, Yamada K, Arakawa K. 1993. In vivo conversion of recombinant human proapolipoprotein AI (rh-Met-proapo AI) to apolipoprotein AI in rabbits. Biochim Biophys Acta 1167: 257-263.
37. Saku K, Bai H, Hirata K, Liu R, Zhang B, Ohkubo K, Yamamoto K, Arakawa K. 1994. In vitro conversion of recombinant human proapolipoprotein A-I to apolipoprotein A-I. Biochim Biophys Acta 1217: 29-30.
38. Schaefer EJ, Zech LA, Jenkins LL, Bronzert TJ, Rubalcaba EA, Lindgren FT, Aamodt RL, Brewer HB, Jr. 1982. Human apolipoprotein A-I and A-II metabolism. J Lipid Res 23: 850-862.
39. Schmidt HH, Genschel J, Haas R, Buttner C, Manns MP. 1997. Expression and purification of recombinant human apolipoprotein A-I in Chinese hamster ovary cells. Protein Expr Purif 10: 226-236.
40. Selimoglu MA, Aydogdu S, Yagci RV. 2002. Lipid parameters in childhood cirrhosis and chronic liver disease. Pediatr Int 44: 400-403.
41. Steel LF, Shumpert D, Trotter M, Seeholzer SH, Evans AA, London WT, Dwek R, Block TM. 2003. A strategy for the comparative analysis of serum proteomes for the discovery of biomarkers for hepatocellular carcinoma. Proteomics 3: 601-609.
42. Tamura K, Dudley J, Nei M, Kumar S. 2007. MEGA4: Molecular Evolutionary Genetics Analysis (MEGA) software version 4.0. Mol Biol Evol 24: 1596-1599.
43. Tennant BC. 2001. Animal models of hepadnavirus-associated hepatocellular carcinoma. Clin Liver Dis 5: 43-68.
44. Tennant BC, Gerin JL. 2001. The woodchuck model of hepatitis B virus infection. Ilar J 42: 89-102.
45. Tennant BC, Toshkov IA, Peek SF, Jacob JR, Menne S, Hornbuckle WE, Schinazi RD, Korba BE, Cote PJ, Gerin JL. 2004. Hepatocellular carcinoma in the woodchuck model of hepatitis B virus infection. Gastroenterology 127: S283-S293.
46. Thompson MM, Reed SC, Cockerill GW. 2004. Therapeutic approaches to raising plasma HDL-cholesterol levels. Nat Clin Pract Cardiovasc Med 1: 84-89.
47. Villeneuve JP. 2005. The natural history of chronic hepatitis B virus infection. J Clin Virol 34: S139-S142.
48. Vishnyakova TG, Bocharov AV, Baranova IN, Chen Z, Remaley AT, Csako G, Eggerman TL, Patterson AP. 2003. Binding and internalization of lipopolysaccharide by Cla-1, a human orthologue of rodent scavenger receptor B1. J Biol Chem 278: 22771-22780.
49. Yang F, Yin Y, Wang F, Zhang L, Wang Y, Sun S. 2010. An altered pattern of liver apolipoprotein A-I isoforms is implicated in male chronic hepatitis B progression. J Proteome Res 9: 134-143.
50. Yim HJ, Lok AS. 2006. Natural history of chronic hepatitis B virus infection: What we knew in 1981 and what we know in 2005. Hepatology 43: S173-S181.
51. Zhang X, Chen B. 2010. Recombinant high density lipoprotein reconstituted with apolipoprotein AI cysteine mutants as delivery vehicles for 10-hydroxycamptothecin. Cancer Lett. 298: 26-33.